Cargando…
COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry
BACKGROUND: The COVID-19 pandemic challenges neurologists in counselling patients with multiple sclerosis (pwMS) regarding their risk by SARS-CoV-2 and in guiding disease-modifying treatment (DMT). OBJECTIVE: To characterize the prevalence and outcome of COVID-19 in pwMS specifically associated with...
Autores principales: | Bsteh, Gabriel, Assar, Hamid, Hegen, Harald, Heschl, Bettina, Leutmezer, Fritz, Di Pauli, Franziska, Gradl, Christiane, Traxler, Gerhard, Zulehner, Gudrun, Rommer, Paulus, Wipfler, Peter, Guger, Michael, Enzinger, Christian, Berger, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315529/ https://www.ncbi.nlm.nih.gov/pubmed/34314457 http://dx.doi.org/10.1371/journal.pone.0255316 |
Ejemplares similares
-
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study
por: Bsteh, Gabriel, et al.
Publicado: (2021) -
Impact of vaccination on COVID‐19 outcome in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2022) -
Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study
por: Bsteh, Gabriel, et al.
Publicado: (2022) -
Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study
por: Bsteh, Gabriel, et al.
Publicado: (2022) -
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)